Urinary Tract Infection Treatment Market: Global Industry Analysis and Opportunity Assessment, 2016-2026

Description: This report offers a 10-year forecast on the urinary tract infection treatment market between 2016 and 2026. In terms of value, the urinary tract infection treatment market is expected to register a CAGR of 2.1% during the forecast period. This study demonstrates market dynamics and trends in major global countries that are expected to influence the current environment and future status of the urinary tract infection treatment market over the forecast period.

Report Description

This report examines the urinary tract infection treatment market for the period 2016-2026. The primary objective of the report is to offer insights into developments in the urinary tract infection treatment market that are significantly helping transform the healthcare industry into a more comprehensive industry.

The urinary tract infection treatment market report begins by defining urinary tract infection and its drug types. It also lists the various indications for urinary tract infections. This is followed by an overview of the urinary tract infection treatment market. The overview section includes analysis of key trends, drivers, restraints, and opportunities that are influencing growth of the global urinary tract infection treatment market currently. Impact analysis of the key growth drivers and restraints based on the weighted average model has also been included in the report to better equip clients with country-specific trends and insights.

The primary driving factors for growth of the urinary tract infection treatment market include significant rising incidence of UTIs and recurring of UTIs, increasing use of urinary catheters and other drainage devices, and increasing incidence of chronic diseases. Furthermore, well established supply chain and ease of market distribution has also triggered growth of the global urinary tract infection treatment market.

On the basis of drug type, the urinary tract infection treatment market is segmented into penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracycline, nitrofurans, and other segment. Penicillin & combinations segment is further sub-segmented into amoxicillin, amoxicillin & clavulanate potassium, and others. Quinolones segment is further sub-segmented into ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin, and others. Cephalosporin segment is further sub-segmented into ceftriaxone, cefuroxime, cefixime, and cephalaxin. Aminoglycoside antibodies segment is further sub-segmented into amikacin and gentamicin. On the basis of indication, the market is segmented complicated urinary tract infection, recurring complicated urinary tract infection, uncomplicated urinary tract infection, and neurogenic bladder infections. A detailed analysis of all categories of application has been provided in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and BPS analysis.

The next section of the report highlights the global urinary tract infection treatment market by region. It provides market outlook for 2016-2026 and sets the forecast within the context of the urinary tract infection treatment market. The study discusses the key regional trends and contracts contributing to growth of the urinary tract infection treatment market across the globe, as well as analyses the extent to which the drivers are influencing this market in these regions. Key markets assessed in this report include North America, Latin America, Eastern Europe, Western Europe, APEJ, Japan, and MEA.

The above sections - by drug type, indication, distribution channel, and regional presence evaluate the present scenario and growth prospects of the urinary tract infection treatment market for the period 2016-2026. We have considered 2015 as the base year and provided data for the forecast period, i.e. 2016-2026.

The forecast presented here assesses the total revenue generated across the urinary tract infection treatment market globally over the forecast period. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the urinary tract infection treatment market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome on the basis of three different types of analysis, i.e. by supply side, downstream industry demand, and economic envelope.
It is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse based on key parameters such as Year-on-Year (Y-o-Y) growth rates, to understand the predictability of the global urinary tract infection treatment market and to identify the right opportunities the market presents.

The global urinary tract infection treatment market segments in terms of drug type, indication type, distribution channel, and regional presence are analysed on the basis of their respective Basis Point (BPS) to understand the individual segment's relative contribution to market growth. This detailed level of information is important for identification of various key trends in the respective market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective.

To understand key growth segments, the author has developed the market 'Attractiveness Index'. The resulting index helps providers to identify real market opportunities.

In the final section of the report, the ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, to get a firm understanding of the key differentiators among competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the urinary tract infection value chain and the potential players with regard to the same. This section also includes market strategies and SWOT analysis of the main players in the market.

Detailed profiles of the medical device companies are also included in the scope of the report to evaluate their long-term and short-term strategies. Key players in the market include Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Inc., F.Hoffmann-La Roche Ltd., Novartis AG. and AstraZeneca plc.

Key Segments Covered:

Drug Type

Penicillin & Combinations
- Amoxicillin
- Amoxicillin & Clavulanate Potassium
- Others

Quinolones
- Ciprofloxacin
- Levofloxacin
- Nalidixic acid
- Norfloxacin
- Others

Cephalosporin
- Ceftriaxone
- Cefuroxime
- Cefixime
- Cephalexin

Aminoglycoside antibiotics
- Amikacin
- Gentamicin
- Sulphonamides
- Azoles and Amphotericin B
- Tetracycline
- Nitrofurans
- Other

By Indication
- Complicated UTI
- Recurring Complicated UTI
- Uncomplicated UTI
- Neurogenic Bladder Infections

By Distribution Channel
- Hospital Pharmacies
- Gynaecology and Urology Clinics
- Drug Store
- Retail Pharmacies
- Online Drug Stores

Key Regions Covered
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- MEA

Key Companies
- Johnson and Johnsons Private Ltd.
- Boehringer Ingelheim GmbH
- Cipla Ltd.
- Bayer AG
- GlaxoSmithKline Pharmaceuticals Ltd.
- Pfizer Inc.
- Hoffmann-La Roche Ltd.
- Novartis AG
- AstraZeneca plc.

Contents:
1. Assumptions and Acronyms Used
2. Research Methodology
3. Executive Summary
4. Urinary Tract Infection Treatment Market Overview
4.1. Introduction
4.1.1. Urinary Tract Infection Treatment Market Taxonomy
4.1.2. Urinary Tract Infection Treatment Market Definition
4.1.3. Urinary Tract Infection Treatment Market Drug Type Overview
4.1.4. Global Antibiotic Drugs Availability and Resistant Timeline
4.1.5. Clinical Trials
4.2. Urinary Tract Infection Treatment Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.2.4. Trends
4.3. Survey Analysis
4.4. Epidemiology Overview
4.5. PEST Analysis
5. Global Urinary Tract Infection Treatment Market Analysis, By Drug Type
5.1. Introduction
5.1.1. Y-o-Y Growth Comparison, By Drug Type
5.1.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
5.1.3. Market Attractiveness Analysis, By Drug Type
5.2. Market Forecast, By Drug Type
5.2.1. Penicillin & Combinations
5.2.1.1. Absolute $ Opportunity
5.2.1.2. Market Value Forecast
5.2.1.3. Amoxicillin
5.2.1.4. Amoxicillin+ Clavulanate Potassium
5.2.1.5. Others
5.2.2. Quinolones
5.2.2.1. Absolute $ Opportunity
5.2.2.2. Market Value Forecast
5.2.2.3. Ciprofloxacin
5.2.2.4. Levofloxacin
5.2.2.5. Nalidixic acid
5.2.2.6. Norfloxacin
5.2.2.7. Others
5.2.3. Cephalosporin
5.2.3.1. Absolute $ Opportunity
5.2.3.2. Market Value Forecast
5.2.3.3. Cefuroxime
5.2.3.4. Ceftriaxone
5.2.3.5. Cefixime
5.2.3.6. Cephalexin
5.2.4. Aminoglycoside Antibiotics
5.2.4.1. Absolute $ Opportunity
5.2.4.2. Market Value Forecast
5.2.4.3. Amikacin
5.2.4.4. Gentamicin
5.2.5. Sulphonamides
5.2.5.1. Absolute $ Opportunity
5.2.5.2. Market Value Forecast
5.2.5.3. Sulfamethoxazole + Trimethoprim
5.2.6. Azoles and Amphotericin B
5.2.6.1. Absolute $ Opportunity
5.2.6.2. Market Value Forecast
5.2.7. Tetracycline
5.2.7.1. Absolute $ Opportunity
5.2.7.2. Market Value Forecast
5.2.7.3. Doxycycline
5.2.8. Nitrofurans
5.2.8.1. Absolute $ Opportunity
5.2.8.2. Market Value Forecast
5.2.8.3. Nitrofurantoin
5.2.9. Others
5.2.9.1. Absolute $ Opportunity
5.2.9.2. Market Value Forecast

6. Global Urinary Tract Infection Treatment Market Analysis, By Distribution Channel

6.1. Introduction
6.1.1. Y-o-Y Growth Comparison, By Distribution Channel
6.1.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
6.1.3. Market Attractiveness Analysis, By Distribution Channel
6.2. Market Forecast, By Distribution Channel
6.2.1. Hospital Pharmacies
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value Forecast
6.2.2. Gynecology and Urology Clinics
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value Forecast
6.2.3. Drug Store
6.2.3.1. Absolute $ Opportunity
6.2.3.2. Market Value Forecast
6.2.4. Retail Pharmacies
6.2.4.1. Absolute $ Opportunity
6.2.4.2. Market Value Forecast
6.2.5. Online Drug Stores
6.2.5.1. Absolute $ Opportunity
6.2.5.2. Market Value Forecast

7. Global Urinary Tract Infection Treatment Market Analysis, By Indication
7.1. Introduction
7.1.1. Y-o-Y Growth Comparison, By Distribution Channel
7.1.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
7.1.3. Market Attractiveness Analysis, By Distribution Channel
7.2. Market Forecast, By Distribution Channel
7.2.1. Complicated UTI
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value Forecast
7.2.2. Recurring Complicated UTI
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value Forecast
7.2.3. Uncomplicated UTI
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value Forecast
7.2.4. Neurogenic Bladder Infections
7.2.4.1. Absolute $ Opportunity
7.2.4.2. Market Value Forecast

8. Global Urinary Tract Infection Treatment Market Analysis, By Region
8.1. Introduction
8.1.1. Y-o-Y Growth Projections, By Region
8.1.2. Market Share & Basis Point (BPS) Analysis, By Region
8.1.3. Regional Attractiveness Analysis
8.2. Market Forecast, By Region
8.2.1. North America Market Value Forecast
8.2.2. Latin America Market Value Forecast
8.2.3. Europe Market Value Forecast
8.2.4. Eastern Europe Market Value Forecast
8.2.5. APEJ Market Value Forecast
8.2.6. Japan Market Value Forecast
8.2.7. MEA Market Value Forecast

9. North America Urinary Tract Infection Treatment Market Analysis
9.1. Market Value Forecast, By Country
9.1.1. Y-o-Y Growth Projections, By Country
9.1.2. Market Share & Basis Point (BPS) Analysis, By Country
9.1.3. Market Attractiveness Analysis, By Country
9.1.4. US
9.1.5. Canada
9.2. Market Value Forecast, By Drug Type
9.2.1. Y-o-Y Growth Projections, By Drug Type
9.2.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
9.2.3. Market Attractiveness Analysis, By Drug Type
9.2.4. Penicillin & Combinations
9.2.4.1. Amoxicillin
9.2.4.2. Amoxicillin+ Clavulanate Potassium
9.2.4.3. Others
9.2.5. Quinolones
9.2.5.1. Ciprofloxacin
9.2.5.2. Levofloxacin
9.2.5.3. Nalidixic acid
9.2.5.4. Norfloxacin
9.2.5.5. Others
9.2.6. Cephalosporin
9.2.6.1. Cefuroxime
9.2.6.2. Ceftriaxone
9.2.6.3. Cefixime
9.2.6.4. Cephalexin
9.2.7. Aminoglycoside Antibiotics
9.2.7.1. Amikacin
9.2.7.2. Gentamicin
9.2.8. Sulphonamides
9.2.8.1. Sulfamethoxazole + Trimethoprim
9.2.9. Azoles and Amphotericin B
9.2.10. Tetracycline
9.2.10.1. Doxycycline
9.2.11. Nitrofurans
9.2.11.1. Nitrofurantoin
9.2.12. Others
9.3. Market Value Forecast, By Distribution Channel
9.3.1. Y-o-Y Growth Projections, By Distribution Channel
9.3.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
9.3.3. Market Attractiveness Analysis, By Distribution Channel
9.3.4. Hospital Pharmacies
9.3.5. Gynecology and Urology Clinics
9.3.6. Drug Stores
9.3.7. Retail Pharmacies
9.3.8. Online Drug Stores
9.4. Market Value Forecast, By Indication
9.4.1. Y-o-Y Growth Projections, By Indication
9.4.2. Market Share & Basis Point (BPS) Analysis, By Indication
9.4.3. Market Attractiveness Analysis, By Indication
9.4.4. Complicated UTI
9.4.5. Recurring Complicated UTI
9.4.6. Uncomplicated UTI
9.4.7. Neurogenic Bladder Infections
10. Latin America Urinary Tract Infection Treatment Market Analysis
10.1. Market Value Forecast, By Country
10.1.1. Y-o-Y Growth Projections, By Country
10.1.2. Market Share & Basis Point (BPS) Analysis, By Country
10.1.3. Market Attractiveness Analysis, By Country
10.1.4. Brazil
10.1.5. Mexico
10.1.6. Rest of Latin America
10.2. Market Value Forecast, By Drug Type
10.2.1. Y-o-Y Growth Projections, By Drug Type
10.2.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
10.2.3. Market Attractiveness Analysis, By Drug Type
10.2.4. Penicillin & Combinations
10.2.4.1. Amoxicillin
10.2.4.2. Amoxicillin+ Clavulanate Potassium
10.2.4.3. Others
10.2.5. Quinolones
10.2.5.1. Ciprofloxacin
10.2.5.2. Levofloxacin
10.2.5.3. Nalidixic acid
10.2.5.4. Norfloxacin
10.2.5.5. Others
10.2.6. Cephalosporin
10.2.6.1. Cefuroxime
10.2.6.2. Ceftriaxone
10.2.6.3. Cefixime
10.2.6.4. Cephalexin
10.2.7. Aminoglycoside Antibiotics
10.2.7.1. Amikacin
10.2.7.2. Gentamicin
10.2.8. Sulphonamides
10.2.8.1. Sulfamethoxazole + Trimethoprim
10.2.9. Azoles and Amphotericin B
10.2.10. Tetracycline
10.2.10.1. Doxycycline
10.2.11. Nitrofurans
10.2.11.1. Nitrofurantoin
10.2.12. Others
10.3. Market Value Forecast, By Distribution Channel
10.3.1. Y-o-Y Growth Projections, By Distribution Channel
10.3.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
10.3.3. Market Attractiveness Analysis, By Distribution Channel
10.3.4. Hospital Pharmacies
10.3.5. Gynecology and Urology Clinics
10.3.6. Drug Stores
10.3.7. Retail Pharmacies
10.3.8. Online Drug Stores
10.4. Market Value Forecast, By Indication
10.4.1. Y-o-Y Growth Projections, By Indication
10.4.2. Market Share & Basis Point (BPS) Analysis, By Indication
10.4.3. Market Attractiveness Analysis, By Indication
10.4.4. Complicated UTI
10.4.5. Recurring Complicated UTI
10.4.6. Uncomplicated UTI
10.4.7. Neurogenic Bladder Infections

11. Western Europe Urinary Tract Infection Treatment Market Analysis
11.1. Market Value Forecast, By Country
11.1.1. Y-o-Y Growth Projections, By Country
11.1.2. Market Share & Basis Point (BPS) Analysis, By Country
11.1.3. Market Attractiveness Analysis, By Country
11.1.4. UK
11.1.5. Germany
11.1.6. France
11.1.7. Spain
11.1.8. Italy
11.1.9. Nordic
11.1.10. Benelux
11.1.11. Rest of Western Europe
11.2. Market Value Forecast, By Drug Type
11.2.1. Y-o-Y Growth Projections, By Drug Type
11.2.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
11.2.3. Market Attractiveness Analysis, By Drug Type
11.2.4. Penicillin & Combinations
11.2.4.1. Amoxicillin
11.2.4.2. Amoxicillin+ Clavulanate Potassium
11.2.4.3. Others
11.2.5. Quinolones
11.2.5.1. Ciprofloxacin
11.2.5.2. Levofloxacin
11.2.5.3. Nalidixic acid
11.2.5.4. Norfloxacin
11.2.5.5. Others
11.2.6. Cephalosporin
11.2.6.1. Cefuroxime
11.2.6.2. Ceftriaxone
11.2.6.3. Cefixime
11.2.6.4. Cephalexin
11.2.7. Aminoglycoside Antibiotics
11.2.7.1. Amikacin
11.2.7.2. Gentamicin
11.2.8.5 Sulphonamides
11.2.8.1. Sulfamethoxazole + Trimethoprim
11.2.9. Azoles and Amphotericin B
11.2.10. Tetracycline
11.2.10.1. Doxycycline
11.2.11. Nitrofurans
11.2.11.1. Nitrofurantoin
11.2.12. Others
11.3. Market Value Forecast, By Distribution Channel
11.3.1. Y-o-Y Growth Projections, By Distribution Channel
11.3.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
11.3.3. Market Attractiveness Analysis, By Distribution Channel
11.3.4. Hospital Pharmacies
11.3.5. Gynecology and Urology Clinics
11.3.6. Drug Stores
11.3.7. Retail Pharmacies
11.3.8. Online Drug Stores
11.4. Market Value Forecast, By Indication
11.4.1. Y-o-Y Growth Projections, By Indication
11.4.2. Market Share & Basis Point (BPS) Analysis, By Indication
11.4.3. Market Attractiveness Analysis, By Indication
11.4.4. Complicated UTI
11.4.5. Recurring Complicated UTI
11.4.6. Uncomplicated UTI
11.4.7. Neurogenic Bladder Infections

12. Eastern Europe Urinary Tract Infection Treatment Market Analysis
12.1. Market Value Forecast, By Country
12.1.1. Y-o-Y Growth Projections, By Country
12.1.2. Market Share & Basis Point (BPS) Analysis, By Country
12.1.3. Market Attractiveness Analysis, By Country
12.1.4. Russia
12.1.5. Poland
12.1.6. Rest of Eastern Europe
12.2. Market Value Forecast, By Drug Type
12.2.1. Y-o-Y Growth Projections, By Drug Type
12.2.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
12.2.3. Market Attractiveness Analysis, By Drug Type
12.2.4. Penicillin & Combinations
12.2.4.1. Amoxicillin
12.2.4.2. Amoxicillin+ Clavulanate Potassium
12.2.4.3. Others
12.2.5. Quinolones
12.2.5.1. Ciprofloxacin
12.2.5.2. Levofoxacin
12.2.5.3. Nalidixic acid
12.2.5.4. Norfloxacin
12.2.5.5. Others
12.2.6. Cephalosporin
12.2.6.1. Cefuroxime
12.2.6.2. Ceftriaxone
12.2.6.3. Cefixime
12.2.6.4. Cephalexin
12.2.7. Aminoglycoside Antibiotics
12.2.7.1. Amikacin
12.2.7.2. Gentamicin
12.2.8. Sulphonamides
12.2.8.1. Sulfamethoxazole + Trimethoprim
12.2.9. Azoles and Amphotericin B
12.2.10. Tetracycline
12.2.10.1. Doxycycline
12.2.11. Nitrofurans
12.2.11.1. Nitrofurantoin
12.2.12. Others
12.3. Market Value Forecast, By Distribution Channel
12.3.1. Y-o-Y Growth Projections, By Distribution Channel
12.3.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
12.3.3. Market Attractiveness Analysis, By Distribution Channel
12.3.4. Hospital Pharmacies
12.3.5. Gynecology and Urology Clinics
12.3.6. Drug Stores
12.3.7. Retail Pharmacies
12.3.8. Online Drug Stores
12.4. Market Value Forecast, By Indication
12.4.1. Y-o-Y Growth Projections, By Indication
12.4.2. Market Share & Basis Point (BPS) Analysis, By Indication
12.4.3. Market Attractiveness Analysis, By Indication
12.4.4. Complicated UTI
12.4.5. Recurring Complicated UTI
12.4.6. Uncomplicated UTI
12.4.7. Neurogenic Bladder Infections

13. APEJ Urinary Tract Infection Treatment Market Analysis
13.1. Market Value Forecast, By Country
13.1.1. Y-o-Y Growth Projections, By Country
13.1.2. Market Share & Basis Point (BPS) Analysis, By Country
13.1.3. Market Attractiveness Analysis, By Country
13.1.4. China
13.1.5. India
13.1.6. ASEAN
13.1.7. Australia & New Zealand
13.1.8. Rest of APEJ
13.2. Market Value Forecast, By Drug Type
13.2.1. Y-o-Y Growth Projections, By Drug Type
13.2.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
13.2.3. Market Attractiveness Analysis, By Drug Type
13.2.4. Penicillin & Combinations
13.2.4.1. Amoxicillin
13.2.4.2. Amoxicillin+ Clavulanate Potassium
13.2.4.3. Others
13.2.5. Quinolones
13.2.5.1. Ciprofloxacin
13.2.5.2. Levofoxacin
13.2.5.3. Nalidixic acid
13.2.5.4. Norfloxacin
13.2.5.5. Others
13.2.6. Cephalosporin
13.2.6.1. Cefuroxime
13.2.6.2. Ceftriaxone
13.2.6.3. Cefixime
13.2.6.4. Cephalexin
13.2.7. Aminoglycoside Antibiotics
13.2.7.1. Amikacin
13.2.7.2. Gentamicin
13.2.8. Sulphonamides
13.2.8.1. Sulfamethoxazole + Trimethoprim
13.2.9. Azoles and Amphotericin B
13.2.10. Tetracycline
13.2.10.1. Doxycycline
13.2.11. Nitrofurans
13.2.11.1. Nitrofurantoin
13.2.12. Others
13.3. Market Value Forecast, By Distribution Channel
13.3.1. Y-o-Y Growth Projections, By Distribution Channel
13.3.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
13.3.3. Market Attractiveness Analysis, By Distribution Channel
13.3.4. Hospital Pharmacies
13.3.5. Gynecology and Urology Clinics
13.3.6. Drug Stores
13.3.7. Retail Pharmacies
13.3.8. Online Drug Stores
13.4. Market Value Forecast, By Indication
13.4.1. Y-o-Y Growth Projections, By Indication
13.4.2. Market Share & Basis Point (BPS) Analysis, By Indication
13.4.3. Market Attractiveness Analysis, By Indication
13.4.4. Complicated UTI
13.4.5. Recurring Complicated UTI
13.4.6. Uncomplicated UTI
13.4.7. Neurogenic Bladder Infections

14. Japan Urinary Tract Infection Treatment Market Analysis
14.1. Market Value Forecast, By Drug Type
14.1.1. Y-o-Y Growth Projections, By Drug Type
14.1.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
14.1.3. Market Attractiveness Analysis, By Drug Type
14.1.4. Penicillin & Combinations
14.1.4.1. Amoxicillin
14.1.4.2. Amoxicillin+ Clavulanate Potassium
14.1.4.3. Others
14.1.5. Quinolones
14.1.5.1. Ciprofloxacin
14.1.5.2. Levofloxacin
14.1.5.3. Nalidixic acid
14.1.5.4. Norfloxacin
14.1.5.5. Others
14.1.6. Cephalosporin
14.1.6.1. Cefuroxime
14.1.6.2. Ceftriaxone
14.1.6.3. Cefixime
14.1.6.4. Cephalexin
14.1.7. Aminoglycoside Antibiotics
14.1.7.1. Amikacin
14.1.7.2. Gentamicin
14.1.8. Sulphonamides
14.1.8.1. Sulphamethoxazole + Trimethoprim
14.1.9. Azoles and Amphotericin B
14.1.10. Tetracycline
14.1.10.1. Doxycycline
14.1.11. Nitrofurans
14.1.11.1. Nitrofurantoin
14.1.12. Others
14.2. Market Value Forecast, By Distribution Channel
14.2.1. Y-o-Y Growth Projections, By Distribution Channel
14.2.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
14.2.3. Market Attractiveness Analysis, By Distribution Channel
14.2.4. Hospital Pharmacies
14.2.5. Gynecology and Urology Clinics
14.2.6. Drug Stores
14.2.7. Retail Pharmacies
14.2.8. Online Drug Stores
14.3. Market Value Forecast, By Indication
14.3.1. Y-o-Y Growth Projections, By Indication
14.3.2. Market Share & Basis Point (BPS) Analysis, By Indication
14.3.3. Market Attractiveness Analysis, By Indication
14.3.4. Complicated UTI
14.3.5. Recurring Complicated UTI
14.3.6. Uncomplicated UTI
14.3.7. Neurogenic Bladder Infections

15. MEA Urinary Tract Infection Treatment Market Analysis
15.1. Market Value Forecast, By Country
15.1.1. Y-o-Y Growth Projections, By Country
15.1.2. Market Share & Basis Point (BPS) Analysis, By Country
15.1.3. Market Attractiveness Analysis, By Country
15.1.4. GCC Countries
15.1.5. South Africa
15.1.6. North Africa
15.1.7. Rest of MEA
15.2. Market Value Forecast, By Drug Type
15.2.1. Y-o-Y Growth Projections, By Drug Type
15.2.2. Market Share & Basis Point (BPS) Analysis, By Drug Type
15.2.3. Market Attractiveness Analysis, By Drug Type
15.2.4. Penicillin & Combinations
15.2.4.1. Amoxicillin
15.2.4.2. Amoxicillin+ Clavulanate Potassium
15.2.4.3. Others
15.2.5. Quinolones
15.2.5.1. Ciprofloxacin
15.2.5.2. Levofloxacin
15.2.5.3. Nalidixic acid
15.2.5.4. Norfloxacin
15.2.5.5. Others
15.2.6. Cephalosporin
15.2.6.1. Cefuroxime
15.2.6.2. Ceftriaxone
15.2.6.3. Cefixime
15.2.6.4. Cephalexin
15.2.7. Aminoglycoside Antibiotics
15.2.7.1. Amikacin
15.2.7.2. Gentamicin
15.2.8. Sulphonamides
15.2.8.1. Sulfamethoxazole + Trimethoprim
15.2.9. Azoles and Amphotericin B
15.2.10. Tetracycline
15.2.10.1. Doxycycline
15.2.11. Nitrofurans
15.2.11.1. Nitrofurantoin
15.2.12. Others
15.3. Market Value Forecast, By Distribution Channel
15.3.1. Y-o-Y Growth Projections, By Distribution Channel
15.3.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel
15.3.3. Market Attractiveness Analysis, By Distribution Channel
15.3.4. Hospital Pharmacies
15.3.5. Gynecology and Urology Clinics
15.3.6. Drug Stores
15.3.7. Retail Pharmacies
15.3.8. Online Drug Stores
15.4. Market Value Forecast, By Indication
15.4.1. Y-o-Y Growth Projections, By Indication
15.4.2. Market Share & Basis Point (BPS) Analysis, By Indication
15.4.3. Market Attractiveness Analysis, By Indication
15.4.4. Complicated UTI
15.4.5. Recurring Complicated UTI
15.4.6. Uncomplicated UTI
15.4.7. Neurogenic Bladder Infections

16. Competition Landscape
16.1. Competition Dashboard
16.2. Company Profiles Inclusions
16.2.1. Revenue
16.2.2. Products/Brand Offerings
16.2.3. Key developments
16.2.4. SWOT Analysis
16.3. Company Profiled
16.3.1. Johnson & Johnson Private Ltd.
16.3.2. Boehringer Ingelheim GmbH
16.3.3. Cipla Ltd.
16.3.4. Bayer AG
16.3.5. GlaxoSmithKline Pharmaceuticals Ltd.
16.3.6. Pfizer Inc.
16.3.7. F. Hoffmann-La Roche Ltd.
16.3.8. Novartis AG
16.3.9. AstraZeneca plc

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3788395/](http://www.researchandmarkets.com/reports/3788395/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Urinary Tract Infection Treatment Market: Global Industry Analysis and Opportunity Assessment, 2016-2026
Web Address: http://www.researchandmarkets.com/reports/3788395/
Office Code: SCBRFNSI

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔️</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔️</td>
<td>USD 7500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔️</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
**Payment Information**

Please indicate the payment method you would like to use by selecting the appropriate box.

- ☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

- ☐ Pay by check: Please post the check, accompanied by this form, to:
  
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- ☐ Pay by wire transfer: Please transfer funds to:
  
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp